HOUSTON, July 10, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the ...
HOUSTON, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results